Author: admin

The Acute Respiratory Distress Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Acute Respiratory Distress Syndrome Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome Market.

Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report:

• Companies across the globe are diligently working toward developing novel Acute Respiratory Distress Syndrome treatment therapies with a considerable amount of success over the years.

• Acute Respiratory Distress Syndrome companies working in the treatment market are RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompé Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy’s and St Thomas’ NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others, are developing therapies for the Acute Respiratory Distress Syndrome treatment

• Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others are expected to have a significant impact on the Acute Respiratory Distress Syndrome market in the coming years.

• In February 2025, Bonus Biogroup (TASE: BONS), a late-stage biotech firm specializing in immunomodulatory and regenerative mesenchymal stromal cell (MSC) therapies, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase III clinical trial in the U.S. The study will assess the safety and effectiveness of MesenCure™—an allogeneic cell therapy composed of enhanced MSCs derived from adipose tissue—for the treatment of respiratory distress in severely ill, hospitalized patients suffering from COVID-19-related pneumonia. MesenCure is designed to address inflammation and tissue damage.

• In January 2025, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapies targeting the complement system, has announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab). This approval covers the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard care and require invasive mechanical ventilation (IMV), with or without extracorporeal membrane oxygenation (ECMO). GOHIBIC is the first and only approved therapy in the EU specifically for SARS-CoV-2-related ARDS.

• In November 2024, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm specializing in anti-inflammatory treatments targeting the complement system, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the marketing authorization of GOHIBIC (vilobelimab). The recommendation supports its use under exceptional circumstances for adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids and invasive mechanical ventilation (IMV), with or without ECMO. The company anticipates a final decision from the European Commission within 67 days.

• In October 2024, BioAegis Therapeutics, an innovative biotech company focused on developing therapies for inflammatory diseases, is excited to announce the enrollment of the first patient in its Phase 2 study of rhu-pGSN for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955).

Acute Respiratory Distress Syndrome Overview

Acute Respiratory Distress Syndrome (ARDS) is a severe condition in which the lungs become inflamed and fill with fluid, leading to difficulty breathing and low oxygen levels in the blood. It can result from various causes, including infections, trauma, pneumonia, or inhalation of harmful substances. Symptoms include shortness of breath, rapid breathing, and low oxygen levels. ARDS is a medical emergency that often requires hospitalization, with treatments including oxygen therapy, mechanical ventilation, and addressing the underlying cause. In severe cases, ARDS can lead to organ failure and may be life-threatening.

Get a Free Sample PDF Report to know more about Acute Respiratory Distress Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight

Emerging Acute Respiratory Distress Syndrome Drugs Under Different Phases of Clinical Development Include:

• RSBT-001: RS BioTherapeutics

• AVM0703: AVM Biotechnology

• CYP 001: Cynata Therapeutics

• AV 001: Vasomune Therapeutics

• ALT-100: Aqualung Therapeutics

• STSA-1002: Staidson (Beijing) Biopharmaceuticals

• GEn-1124: GEn1E Lifesciences

• Descartes 30: Cartesian Therapeutics

• Rhu-pGSN: BioAegis Therapeutics Inc.

• ExoFlo: Direct Biologics, LLC

• Reparixin 600mg: Dompé Farmaceutici S.p.A

• Centhaquine: Pharmazz, Inc.

• ALT-100 mAb: Aqualung Therapeutics Corp.

• MRG-001: MedRegen LLC

• TTI-0102: Thiogenesis Therapeutics, Inc.

• Dexamethasone: Hospital Universitario Infanta Leonor

• Isoflurane: Guy’s and St Thomas’ NHS Foundation Trust

• Pirfenidone/Placebo: Fujian Medical University

• Trimodulin: Biotest

• AeroFact: Aerogen Pharma Limited

• Ibudilast: MediciNova

• Poractant Alfa: NorthShore University HealthSystem

• Tozorakimab: AstraZeneca

• L-citrulline: Asklepion Pharmaceuticals

Acute Respiratory Distress Syndrome Route of Administration

Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

• Molecule Type

Acute Respiratory Distress Syndrome Molecule Type

Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment

• Acute Respiratory Distress Syndrome Assessment by Product Type

• Acute Respiratory Distress Syndrome By Stage and Product Type

• Acute Respiratory Distress Syndrome Assessment by Route of Administration

• Acute Respiratory Distress Syndrome By Stage and Route of Administration

• Acute Respiratory Distress Syndrome Assessment by Molecule Type

• Acute Respiratory Distress Syndrome by Stage and Molecule Type

DelveInsight’s Acute Respiratory Distress Syndrome Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Acute Respiratory Distress Syndrome product details are provided in the report. Download the Acute Respiratory Distress Syndrome pipeline report to learn more about the emerging Acute Respiratory Distress Syndrome therapies

Some of the key companies in the Acute Respiratory Distress Syndrome Therapeutics Market include:

Key companies developing therapies for Acute Respiratory Distress Syndrome are – Fisher & Paykel Healthcare Limited, NRx Pharmaceuticals, Inc., Faron Pharmaceuticals, BioMarck Pharmaceuticals, GE Healthcare, Hamilton Company, Athersys, United Therapeutics, Apeptico Forschung, HEALIOS K.K, Dragerwerk AG & Co. KGaA, ALung Technologies, Inc ( LivaNova PLC), and others.

Acute Respiratory Distress Syndrome Pipeline Analysis:

The Acute Respiratory Distress Syndrome pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Respiratory Distress Syndrome with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Respiratory Distress Syndrome Treatment.

• Acute Respiratory Distress Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Acute Respiratory Distress Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Respiratory Distress Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Respiratory Distress Syndrome drugs and therapies

Acute Respiratory Distress Syndrome Pipeline Market Drivers

• Rising incidence of Acute Respiratory Distress Syndrome, the rising geriatric population are some of the important factors that are fueling the Acute Respiratory Distress Syndrome Market.

Acute Respiratory Distress Syndrome Pipeline Market Barriers

• However, increasing Cost of Treatment Therapeutics, lack of Skilled Professionals and other factors are creating obstacles in the Acute Respiratory Distress Syndrome Market growth.

Scope of Acute Respiratory Distress Syndrome Pipeline Drug Insight

• Coverage: Global

• Key Acute Respiratory Distress Syndrome Companies: RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompé Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy’s and St Thomas’ NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others

• Key Acute Respiratory Distress Syndrome Therapies: RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others

• Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies

• Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers

Request for Sample PDF Report for Acute Respiratory Distress Syndrome Pipeline Assessment and clinical trials

Table of Contents

1. Acute Respiratory Distress Syndrome Report Introduction

2. Acute Respiratory Distress Syndrome Executive Summary

3. Acute Respiratory Distress Syndrome Overview

4. Acute Respiratory Distress Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Acute Respiratory Distress Syndrome Pipeline Therapeutics

6. Acute Respiratory Distress Syndrome Late Stage Products (Phase II/III)

7. Acute Respiratory Distress Syndrome Mid Stage Products (Phase II)

8. Acute Respiratory Distress Syndrome Early Stage Products (Phase I)

9. Acute Respiratory Distress Syndrome Preclinical Stage Products

10. Acute Respiratory Distress Syndrome Therapeutics Assessment

11. Acute Respiratory Distress Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Respiratory Distress Syndrome Key Companies

14. Acute Respiratory Distress Syndrome Key Products

15. Acute Respiratory Distress Syndrome Unmet Needs

16 . Acute Respiratory Distress Syndrome Market Drivers and Barriers

17. Acute Respiratory Distress Syndrome Future Perspectives and Conclusion

18. Acute Respiratory Distress Syndrome Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Respiratory Distress Syndrome Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | RS BioTherapeutics, AVM Biotech, Cynata Therapeutics

“Primary Biliary Cholangitis Market Insight, Epidemiology, and Market Forecast – 2034”

DelveInsight’s “Primary Biliary Cholangitis Market Insight, Epidemiology, and Market Forecast – 2034” report delivers comprehensive insights into the PBC market, including historical and forecasted epidemiology as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.

The primary biliary cholangitis market size was USD 1.2 billion across the 7MM in 2023, which is forecasted to increase steadily from 2024 to 2034. Furthermore, the US accounted for the largest PBC market share. This trend is expected to continue in the forecasted period, due to a larger patient pool, better disease awareness, and favourable reimbursement policies.

Download the Primary Biliary Cholangitis Market Forecast Report to understand which factors are driving the Primary Biliary Cholangitis market @ Primary Biliary Cholangitis Market Trends.

The report provides detailed epidemiological data segmentation covering total diagnosed prevalent cases, gender-specific diagnosed prevalent cases, and age-specific diagnosed prevalent cases of primary biliary cholangitis across the 7MM during the study period (2020-2034).

According to the primary biliary cholangitis epidemiology contained in the report, the US accounted for the largest proportion of diagnosed prevalent PBC cases among the 7MM in 2023. Furthermore, the epidemiology model reveals a significantly higher prevalence among females compared to males across all markets, attributable to genetic predisposition, hormonal influences, and environmental factors. Among European nations, Germany reported the highest burden, followed by Italy and the UK. The data also indicates that PBC predominantly affects individuals aged 40-70 years, reinforcing the importance of age-targeted screening and treatment strategies.

Discover evolving trends in the Primary Biliary Cholangitis patient pool forecasts @ Primary Biliary Cholangitis Epidemiological Analysis.

The current primary biliary cholangitis treatment landscape has been historically dominated by ursodeoxycholic acid (UDCA) as the cornerstone first-line therapy, with obeticholic acid (OCALIVA) from Intercept Pharmaceuticals serving as the second-line option for patients with inadequate response to or intolerance of UDCA. However, the therapeutic paradigm has experienced significant evolution in 2024 with the FDA granting accelerated approvals to two novel treatments: Elafibranor (IQIRVO) in June 2024 by Genfit/Ipsen and Seladelpar (LIVDELZI) in August 2024 by Gilead Sciences. Both therapeutics represent innovative approaches targeting peroxisome proliferator-activated receptors, offering new mechanisms to address the complex primary biliary cholangitis pathophysiology.

The primary biliary cholangitis clinical trials market is demonstrating robust activity, with several promising candidates advancing through the development pipeline. Saroglitazar Magnesium by Zydus Therapeutics, a dual PPAR alpha/gamma agonist with the FDA Fast Track and Orphan Drug designations, shows substantial potential in addressing both cholestasis and metabolic aspects of PBC. A Phase IIb/III trial (NCT05133336) is ongoing to further evaluate its dual PPAR alpha/gamma agonism targeting metabolic and inflammatory pathways.

GlaxoSmithKline’s Linerixibat, an IBAT inhibitor currently in Phase III trials, targets the debilitating pruritus associated with PBC. Additionally, COUR Pharmaceuticals’ CNP-104 secured FDA Orphan Drug Designation in January 2025, positioning it as potentially the first disease-modifying treatment for PBC by inducing tolerance to pathogenic activated PDC-E2 T-cells that drive bile duct inflammation.

Discover evolving trends in the Primary Biliary Cholangitis treatment landscape @ Primary Biliary Cholangitis Recent Developments.

Despite these significant advancements, the PBC market faces several challenges, including insufficient disease awareness among healthcare providers and patients, complex diagnostic processes resulting in under-recognition, and affordability barriers to innovative treatments. Addressing these obstacles will require comprehensive educational initiatives, streamlined diagnostic pathways, and creative pricing strategies to improve treatment accessibility.

Furthermore, safety concerns continue to emerge, as evidenced by the FDA’s recent identification of serious liver injury cases in non-cirrhotic PBC patients treated with obeticholic acid. This new safety concern was announced in a Drug Safety Communication in December 2024, following a review of postmarket clinical trial data, highlighting the ongoing need for vigilant safety monitoring of both established and emerging therapies.

The primary biliary cholangitis competitive landscape is evolving rapidly, with several key players actively involved in therapeutic development and commercialization. Some of the pharmaceutical companies active in this landscape include Gilead Sciences (NASDAQ: GILD), Intercept Pharmaceuticals (NASDAQ: ICPT), CymaBay Therapeutics (NASDAQ: CBAY), COUR Pharmaceuticals, Teva Pharmaceutical (NYSE: TEVA), Mylan, AbbVie (NYSE: ABBV), Glenmark Pharmaceuticals (NSE: GLENMARK), Allergan, Eli Lilly (NYSE: LLY), Novartis (NYSE: NVS), Pfizer (NYSE: PFE), Roche (SWX: ROG), Merck (NYSE: MRK), Bristol-Myers Squibb (NYSE: BMY), AstraZeneca (NASDAQ: AZN), GlaxoSmithKline (NYSE: GSK), Takeda (NYSE: TAK), Amgen (NASDAQ: AMGN), Boehringer Ingelheim, Dr. Reddy’s (NYSE: RDY), Amneal (NASDAQ: AMRX), Alnylam (NASDAQ: ALNY), Ionis (NASDAQ: IONS), Arrowhead (NASDAQ: ARWR), CureVac (NASDAQ: CVAC), Sangamo (NASDAQ: SGMO), Calliditas Therapeutics (NASDAQ: CALT), NGM Biopharmaceuticals (NASDAQ: NGM), Bluebird Bio (NASDAQ: BLUE), Intellia (NASDAQ: NTLA), Albireo, TARGET PharmaSolutions, Genfit (NASDAQ: GNFT), and Ascletis Pharma, among others.

Looking ahead, DelveInsight forecasts the primary biliary cholangitis market will witness accelerated growth driven by the continued uptake of newly approved therapies and the potential introduction of pipeline candidates addressing unmet needs. The integration of biomarker-guided treatment approaches and combination regimens is anticipated to optimize therapeutic outcomes, while ongoing research into disease-modifying interventions may fundamentally transform the treatment paradigm. As the understanding of PBC pathophysiology advances, the market is poised for further innovation, with the ultimate goal of improving quality of life and long-term outcomes for patients living with this challenging autoimmune liver condition.

Table of Contents

1. Key Insights

2. Executive Summary of Primary Biliary Cholangitis

3. Primary Biliary Cholangitis Competitive Intelligence

4. Primary Biliary Cholangitis: Market Overview at a Glance

5. Primary Biliary Cholangitis: Disease Background and Overview

6. Patient Journey

7. Primary Biliary Cholangitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Primary Biliary Cholangitis Unmet Needs

10. Key Endpoints of Primary Biliary Cholangitis Treatment

11. Primary Biliary Cholangitis Marketed Products

12. Primary Biliary Cholangitis Emerging Therapies

13. Primary Biliary Cholangitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Primary Biliary Cholangitis

17. KOL Views

18. Primary Biliary Cholangitis Market Drivers

19. Primary Biliary Cholangitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports

Primary Biliary Cholangitis Pipeline Insight

Primary Biliary Cholangitis Pipeline Insight provides comprehensive insights about the Primary Biliary Cholangitis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Primary Biliary Cholangitis companies, including Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Calliditas Therapeutics, Dr Falk Pharma, Mirum Pharmaceuticals, and GlaxoSmithKline, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Biliary Cholangitis Treatment Market Valued at USD 1.2 Billion in 2023; Projected to Grow Significantly Through 2034 Driven by Anticipated Pipeline Drugs | DelveInsight

DelveInsight’s “Dupuytren’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dupuytren’s Disease, historical and forecasted epidemiology as well as the Dupuytren’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Dupuytren’s Disease, offering comprehensive insights into the Dupuytren’s Disease revenue trends, prevalence, and treatment landscape. The report delves into key Dupuytren’s Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Dupuytren’s Disease therapies. Additionally, we cover the landscape of Dupuytren’s Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Dupuytren’s Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Dupuytren’s Disease space.

To Know in detail about the Dupuytren’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dupuytren’s Disease Market Forecast

Some of the key facts of the Dupuytren’s Disease Market Report:

• The Dupuytren’s Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In July 2024, Connext has announced the successful first administration of CNT201, its therapeutic treatment for Dupuytren’s contracture, in patients. Dupuytren’s contracture is a debilitating condition where fibrosis develops in the fascia between the skin and tendons of the palm due to collagen accumulation, leading to permanently bent fingers and severely affecting the patient’s quality of life. At present, no definitive cure exists for this condition.

• Key Dupuytren’s Disease Companies: Endo Pharmaceuticals/ Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences, and others

• Key Dupuytren’s Disease Therapies: XIAFLEX (clostridium histolyticum), Anti-TNF drug adalimumab, VEN201, and others

• The Dupuytren’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dupuytren’s Disease pipeline products will significantly revolutionize the Dupuytren’s Disease market dynamics.

• A study conducted by Broekstra et al. (2022) identified 38,707 individuals with Dupuytren’s disease in a population-based dynamic cohort, indicating a point prevalence of 0.67% in 2013. Of the affected individuals, 64.6% were male and 35.3% were female.

• According to a study by Sasaki et al. (2021) conducted in Japan, Dupuytren’s disease was identified in 44 individuals, reflecting an overall prevalence of 3.9%. Among men, the prevalence was 8.3%, while among women it was 1.3%. In participants over the age of 60, the prevalence increased to 7.7%—with 18.5% in men and 2.4% in women.

Dupuytren’s Disease Overview

Dupuytren’s Disease, also known as Dupuytren’s Contracture, is a progressive hand condition where the connective tissue (fascia) under the skin of the palm thickens and tightens. Over time, this can cause one or more fingers—most commonly the ring and little fingers—to bend inward toward the palm, making it difficult to fully straighten them.

It typically develops slowly and is more common in older adults, particularly males of Northern European descent. While it is usually painless, it can impact hand function and quality of life in advanced cases. Treatment options range from non-surgical therapies like injections to surgical procedures to release the contracted tissue.

Get a Free sample for the Dupuytren’s Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/dupuytrens-disease-market

Dupuytren’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dupuytren’s Disease Epidemiology Segmentation:

The Dupuytren’s Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Dupuytren’s Disease

• Prevalent Cases of Dupuytren’s Disease by severity

• Gender-specific Prevalence of Dupuytren’s Disease

• Diagnosed Cases of Episodic and Chronic Dupuytren’s Disease

Download the report to understand which factors are driving Dupuytren’s Disease epidemiology trends @ Dupuytren’s Disease Epidemiology Forecast

Dupuytren’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dupuytren’s Disease market or expected to get launched during the study period. The analysis covers Dupuytren’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dupuytren’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dupuytren’s Disease Therapies and Key Companies

• XIAFLEX (clostridium histolyticum): Endo Pharmaceuticals/ Asahi Kasei Pharma

• Anti-TNF drug adalimumab: 180 Life Sciences

• VEN201: Ventoux Biosciences

• Adalimumab: 180 Life Sciences

Discover more about therapies set to grab major Dupuytren’s Disease market share @ Dupuytren’s Disease Treatment Landscape

Dupuytren’s Disease Market Drivers

• Awareness of Dupuytren’s Disease has improved over time, leading to earlier diagnosis and intervention.

• There have been advancements in both surgical and non-surgical treatment options for Dupuytren’s Disease, offering patients more choices for managing their condition.

Dupuytren’s Disease Market Barriers

• There is growing interest in minimally invasive treatment options for Dupuytren’s Disease, which could offer reduced recovery times and improved patient outcomes.

• Advancements in genetics and personalized medicine may lead to the development of tailored treatment approaches based on individual patient characteristics, potentially enhancing treatment efficacy

Scope of the Dupuytren’s Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Dupuytren’s Disease Companies: Endo Pharmaceuticals/ Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences, and others

• Key Dupuytren’s Disease Therapies: XIAFLEX (clostridium histolyticum), Anti-TNF drug adalimumab, VEN201, and others

• Dupuytren’s Disease Therapeutic Assessment: Dupuytren’s Disease current marketed and Dupuytren’s Disease emerging therapies

• Dupuytren’s Disease Market Dynamics: Dupuytren’s Disease market drivers and Dupuytren’s Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Dupuytren’s Disease Unmet Needs, KOL’s views, Analyst’s views, Dupuytren’s Disease Market Access and Reimbursement

To know more about Dupuytren’s Disease companies working in the treatment market, visit @ Dupuytren’s Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Dupuytren’s Disease Market Report Introduction

2. Executive Summary for Dupuytren’s Disease

3. SWOT analysis of Dupuytren’s Disease

4. Dupuytren’s Disease Patient Share (%) Overview at a Glance

5. Dupuytren’s Disease Market Overview at a Glance

6. Dupuytren’s Disease Disease Background and Overview

7. Dupuytren’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Dupuytren’s Disease

9. Dupuytren’s Disease Current Treatment and Medical Practices

10. Dupuytren’s Disease Unmet Needs

11. Dupuytren’s Disease Emerging Therapies

12. Dupuytren’s Disease Market Outlook

13. Country-Wise Dupuytren’s Disease Market Analysis (2020–2034)

14. Dupuytren’s Disease Market Access and Reimbursement of Therapies

15. Dupuytren’s Disease Market Drivers

16. Dupuytren’s Disease Market Barriers

17. Dupuytren’s Disease Appendix

18. Dupuytren’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dupuytren’s Disease Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Endo Pharma, Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences

“Patient Monitoring Devices – Market Insight, Competitive Landscape, and Market Forecast, 2030”

DelveInsight’s “Patient Monitoring Devices – Market Insight, Competitive Landscape, and Market Forecast, 2030” report provides in-depth analysis of patient monitoring devices market dynamics, epidemiology trends, and emerging technologies that will shape the future of patient monitoring. The global patient monitoring devices market, valued at approximately USD 35 billion in 2023, is projected to grow at a CAGR of 8.20% during the forecast period from 2024 to 2030, reaching ~USD 56 billion by 2030. This growth trajectory reflects the escalating demand for technologies that enable continuous assessment of vital parameters across diverse healthcare environments.

North America currently dominates the patient monitoring devices market, driven by high chronic disease prevalence, advanced healthcare infrastructure, and favorable reimbursement policies. The region’s leadership is further strengthened by government initiatives supporting remote patient monitoring programs and telemedicine services, which were particularly accelerated by healthcare adaptations during the COVID-19 pandemic. Meanwhile, the Asia Pacific region is anticipated to experience the fastest growth during the forecast period, propelled by increasing healthcare expenditure and rising disease burden.

Download the Patient Monitoring Devices Market Forecast Report to understand which factors are driving the Patient Monitoring Devices market @ Patient Monitoring Devices Market Trends.

The epidemiological landscape underscores the urgent need for advanced monitoring solutions. Currently, nearly 600 million adults worldwide are living with diabetes – approximately one in nine individuals – with projections indicating this number will surge to over 850 million by 2050. Similarly, cardiovascular diseases remain the leading global cause of mortality, affecting more than 620 million people and causing approximately 21 million deaths annually. These statistics highlight the critical role of continuous monitoring in disease management and early intervention strategies.

Within the market segments, cardiac monitoring devices hold a significant share, primarily due to the high global burden of cardiovascular disorders. Blood glucose monitoring systems are also witnessing substantial growth, currently representing approximately 24% of the market share, as diabetes management increasingly relies on real-time data to optimize treatment outcomes.

Download the Patient Monitoring Devices Competitive Landscape Report for in-depth Patient Monitoring Devices competitive insights.

Recent developments in the market showcase the industry’s innovation trajectory. In November 2024, BioIntelliSense received FDA approval for its BioButton Multi-Patient wearable and BioDashboard system, designed to enhance hospital-based virtual care programs and extend patient monitoring capabilities into home environments. Earlier in October 2024, the company also secured FDA clearance for its rechargeable BioButton Multi-Patient wearable, expanding its continuous patient monitoring portfolio with reusable solutions for automating vital sign collection across various healthcare settings. Additionally, Sibel Health announced in March 2025 the closing of $30 million in new equity funding to advance its remote monitoring technologies.

The integration of artificial intelligence, Internet of Medical Things (IoMT), and advanced biosensors is rapidly transforming patient monitoring capabilities. Smart monitoring devices with wireless connectivity enable seamless data transmission and analysis, which facilitates early detection of deterioration conditions and supports timely intervention. The shift toward value-based healthcare models is further accelerating the adoption of remote patient monitoring technologies that reduce hospital readmissions and improve patient outcomes while decreasing overall healthcare costs.

Discover evolving trends in the Patient Monitoring Devices landscape @ Patient Monitoring Devices Recent Developments.

Looking ahead, the patient monitoring devices market faces both opportunities and challenges. While technological advancements continue to enhance monitoring capabilities, issues related to data security, interoperability, and the high cost of premium devices remain significant barriers to universal adoption. Nevertheless, the market’s trajectory signals a transformative period in healthcare delivery, wherein continuous monitoring becomes increasingly integral to chronic disease management, preventive care, and personalized medicine approaches.

Table of Contents

1. Patient Monitoring Devices Market Report Introduction

2. Patient Monitoring Devices Market Executive Summary

3. Regulatory Analysis

4. Patient Monitoring Devices Market Key Factors Analysis

5. Patient Monitoring Devices Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Patient Monitoring Devices Market

7. Patient Monitoring Devices Market Layout

8. Patient Monitoring Devices Global Company Share Analysis – Key 3-5 Companies

9. Patient Monitoring Devices Company and Product Profiles

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Patient Monitoring Devices Market Projected to Reach ~USD 56 Billion by 2030, Driven by Advanced AI Integration and Recent FDA Clearances | DelveInsight

“Andersen-Tawil Syndrome Market Insights, Epidemiology, and Market Forecast – 2032”

DelveInsight’s “Andersen-Tawil Syndrome Market Insights, Epidemiology, and Market Forecast – 2032” report delivers comprehensive insights into this rare genetic condition, including historical and forecasted epidemiology as well as the Andersen-Tawil syndrome market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The report provides a detailed analysis of current treatment practices, emerging therapies, market share of individual treatments, and projected market size from till 2032. Additionally, it examines key market drivers, barriers, and unmet medical needs that influence the Andersen-Tawil syndrome therapeutic landscape.

According to the report, the Andersen-Tawil syndrome market is going to expand notably across 7MM, driven by advancements in genetic diagnostics, precision medicine, and increased research into rare diseases. Key trends include the development of gene therapies, potassium channel modulators, and AI-driven diagnostic tools, alongside regulatory incentives for orphan drug development. Furthermore, the US holds the largest market share due to robust healthcare infrastructure, research funding, and early adoption of targeted therapies.

Download the Andersen-Tawil Syndrome Market Forecast Report to understand which factors are driving the Andersen-Tawil Syndrome market @ Andersen-Tawil Syndrome Market Trends.

Andersen-Tawil syndrome is a rare genetic disorder characterized by a clinical triad of periodic paralysis, cardiac arrhythmias, and distinctive physical features. The condition results primarily from mutations in the KCNJ2 gene, which encodes the inward-rectifying potassium channel Kir2.1. This channelopathy represents the first identified link between cardiac and skeletal muscle excitability, making it a unique therapeutic target.

According to DelveInsight’s epidemiological analysis, while the precise Andersen-Tawil syndrome prevalence data is limited by the condition’s rarity, with an estimated prevalence of 1 in 1 million people worldwide. However, improved molecular diagnostic techniques are enabling better identification of affected individuals. The comprehensive epidemiological segmentation in the report provides valuable insights into diagnosed prevalent cases, type-specific cases, and treatment patterns across the 7MM, offering strategic guidance for healthcare stakeholders and pharmaceutical developers.

Discover evolving trends in the Andersen-Tawil Syndrome patient pool forecasts @ Andersen-Tawil Syndrome Epidemiological Analysis.

The current Andersen-Tawil syndrome treatment landscape primarily focuses on the management of symptoms rather than addressing the underlying genetic cause. For cardiac manifestations, beta-blockers like propranolol and anti-arrhythmic medications such as flecainide are commonly prescribed, while periodic paralysis is typically managed with carbonic anhydrase inhibitors, including acetazolamide and dichlorphenamide. Recent clinical evidence suggests that dichlorphenamide may offer superior efficacy in reducing paralytic attacks compared to acetazolamide in some patients. In severe cases with life-threatening arrhythmias, implantable cardioverter-defibrillators may be necessary, though this intervention requires careful evaluation of the risk-benefit profile, especially in pediatric and adolescent populations.

The Andersen-Tawil syndrome pipeline is evolving with pharmaceutical companies exploring novel therapeutic approaches targeting the underlying ion channel dysfunction. Current research is focusing on developing therapies that can potentially restore normal potassium channel function, with particular attention to addressing the KCNJ2 mutations that account for approximately 60% of cases. Emerging investigations into PIP2 regulation of the Kir2.1 potassium channel may provide new therapeutic targets, as recent research has identified impaired PIP2 regulation as a significant pathophysiological mechanism in ATS.

Recent developments in the Andersen-Tawil syndrome treatment landscape highlight several advances. A March 2025 study showed that the severity of potassium channel dysfunction in Andersen-Tawil syndrome directly affects muscle weakness, with both high and low potassium levels triggering symptoms depending on the mutation’s impact. Additionally, a September 2024 clinical study in China detailed new KCNJ2 gene mutations and emphasized the importance of genetic testing and potassium supplementation in managing Andersen-Tawil syndrome symptoms.

Discover evolving trends in the Andersen-Tawil Syndrome treatment landscape @ Andersen-Tawil Syndrome Recent Developments.

Despite promising developments, significant challenges remain in the Andersen-Tawil syndrome market, including the heterogeneous clinical presentation that complicates diagnosis, limited patient populations for clinical trials, and the need for long-term safety and efficacy data for emerging therapies. Additionally, the high cost of novel treatments may present access barriers, particularly in regions with restrictive reimbursement policies for rare disease therapies.

Looking ahead, the Andersen-Tawil syndrome market is expected to witness notable growth mainly due to an increased disease awareness among healthcare providers, advancements in genetic testing enabling earlier and more accurate diagnosis, and the potential introduction of precision medicine approaches targeting specific genetic variants. The orphan disease status of Andersen-Tawil syndrome provides incentives for pharmaceutical companies to invest in this area, potentially accelerating the development of innovative treatments for this underserved patient population.

DelveInsight’s analysis emphasizes the importance of collaborative research initiatives, patient registries, and biomarker development to advance understanding of Andersen-Tawil syndrome pathophysiology and facilitate targeted therapeutic approaches. As molecular diagnostic techniques continue to improve and our understanding of ion channel dynamics expands, the Andersen-Tawil syndrome market is positioned for innovation that could substantially improve outcomes for patients with this challenging disorder.

Table of Contents

1. Key Insights

2. Executive Summary of Andersen-Tawil Syndrome

3. Andersen-Tawil Syndrome Competitive Intelligence

4. Andersen-Tawil Syndrome: Market Overview at a Glance

5. Andersen-Tawil Syndrome: Disease Background and Overview

6. Patient Journey

7. Andersen-Tawil Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Andersen-Tawil Syndrome Unmet Needs

10. Key Endpoints of Andersen-Tawil Syndrome Treatment

11. Andersen-Tawil Syndrome Marketed Products

12. Andersen-Tawil Syndrome Emerging Therapies

13. Andersen-Tawil Syndrome: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Andersen-Tawil Syndrome

17. KOL Views

18. Andersen-Tawil Syndrome Market Drivers

19. Andersen-Tawil Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Andersen-Tawil Syndrome Market Set for Notable Growth Through 2032 Amid Advances in Genetic Diagnostics and Targeted Therapies | DelveInsight

“Retinal Edema – Market Insight, Epidemiology And Market Forecast – 2032”

DelveInsight’s “Retinal Edema – Market Insight, Epidemiology And Market Forecast – 2032” report delivers an in-depth understanding of the retinal edema treatment market, historical and forecasted epidemiology, and market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The report further assesses current treatment practices, emerging drugs, and retinal edema market drivers, providing a comprehensive overview of the factors influencing this rapidly evolving therapeutic landscape.

The retinal edema treatment market is experiencing strong growth across the 7MM, driven by rising cases of diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion. Furthermore, the US holds the largest retinal edema market share, mainly due to a large patient pool, high adoption of advanced therapies, and ongoing research and development activities, which collectively drive greater demand and higher spending on treatment.

Download the Retinal Edema Market Forecast Report to understand which factors are driving the Retinal Edema market @ Retinal Edema Market Trends.

Retinal edema epidemiological studies indicate an increasing prevalence in all the major markets, mainly due to rising rates of diabetes, aging populations, and associated conditions like diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion. Additionally, diabetic macular edema represents one of the most prevalent forms of retinal edema. According to DelveInsight’s research, more than 5% of people with diabetes globally have diabetic macular edema, with prevalence rates varying across regions. Among patients with type 1 diabetes, diabetic macular edema prevalence ranges between 4.2% and 8%, while in patients with type 2 diabetes, prevalence ranges from 1.5% to 13%.

Discover evolving trends in the Retinal Edema patient pool forecasts @ Retinal Edema Epidemiological Analysis.

The current retinal edema treatment landscape is dominated by anti-VEGF therapies, which effectively reduce fluid buildup and improve vision. Key drugs include EYLEA HD (aflibercept) from Regeneron Pharmaceuticals (NASDAQ: REGN) and Bayer (ETR: BAYN), offering extended dosing intervals. VABYSMO (faricimab-svoa), developed by Genentech, represents a groundbreaking advancement as the first and only FDA-approved injectable eye medicine for both wet AMD and DME. Biosimilars like BYOOVIZ (Samsung Bioepis) and YESAFILI (Biocon Biologics) provide more cost-effective options with similar efficacy. Other notable companies in the field are Novartis, Genentech, and AbbVie, all contributing to ongoing innovation, including long-acting drug delivery systems and emerging oral therapies.

According to DelveInsight’s pipeline analysis of retinal edema treatments, several biopharmaceutical companies, including Roche, Genentech, Kodiak Sciences, Outlook Therapeutics, Taiwan Liposome Company, and Ocuphire, are making significant progress in developing advanced therapies that could transform care for this condition.

Kodiak Sciences is advancing tarcocimab tedromer (KSI-301), which is engineered for extended durability in treating retinal vein occlusion and diabetic macular edema (DME). They are also working on KSI-101, which targets macular edema caused by inflammation and DME. Both treatments are currently in late-stage clinical trials.

Outlook Therapeutics is progressing with LYTENAVA (ONS-5010), a novel ophthalmic formulation of bevacizumab specifically designed for retinal diseases. Meanwhile, the Taiwan Liposome Company is developing TLC399 (ProDex), a long-acting injectable form of dexamethasone that uses a proprietary sustained-release delivery platform to treat macular edema.

In addition, oral therapies are emerging in this field, including APX3330 by Ocuphire, a Ref-1 inhibitor currently in development for diabetic retinopathy.

The report also offers a thorough analysis of recent developments in the retinal edema therapeutic landscape and discusses their implications for the competitive environment surrounding this condition.

In early 2025, several important FDA approvals and clinical trial updates have influenced the retinal edema treatment landscape. In February 2025, the FDA approved Roche’s Susvimo (ranibizumab injection) for diabetic macular edema. This marked the introduction of the first continuous delivery treatment for diabetic macular edema, significantly reducing the need for frequent eye injections. Additionally, in March 2025, the FDA approved ENCELTO (revakinagene taroretcel-lwey), developed by Neurotech Pharmaceuticals, as the first treatment for Macular Telangiectasia type 2, utilizing an innovative encapsulated cell therapy platform.

New clinical trials are also in progress, including studies of a higher-dose aflibercept by Bayer for treating macular edema secondary to retinal vein occlusion, and Unity Biotechnology’s Phase III trial of foselutoclax for diabetic macular edema.

Discover evolving trends in the Retinal Edema treatment landscape @ Retinal Edema Recent Developments.

Despite these advancements, there are several retinal edema market challenges. In April 2025, the FDA delivered a complete response letter for longer dosage intervals (24 weeks) in aflibercept for DME and wet AMD, indicating regulatory hurdles for extended treatment protocols. Additionally, inconsistencies in diagnostic approaches and limited access to specialized eye care remain barriers to optimal patient management across different regions.

Looking ahead, the retinal edema market is poised for continued growth driven by several factors, including the integration of AI in imaging diagnostics and personalized treatment approaches based on molecular profiling. As research continues to uncover the complex pathophysiology of retinal edema and associated conditions, the market is expected to expand substantially, offering more tailored treatment options and improved outcomes for patients suffering from this vision-threatening condition.

Table of Contents

1. Key Insights

2. Executive Summary of Retinal Edema

3. Retinal Edema Competitive Intelligence

4. Retinal Edema: Market Overview at a Glance

5. Retinal Edema: Disease Background and Overview

6. Patient Journey

7. Retinal Edema Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Retinal Edema Unmet Needs

10. Key Endpoints of Retinal Edema Treatment

11. Retinal Edema Marketed Products

12. Retinal Edema Emerging Therapies

13. Retinal Edema: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Retinal Edema

17. KOL Views

18. Retinal Edema Market Drivers

19. Retinal Edema Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports

Retinal Edema Pipeline Insight

Retinal Edema Pipeline Insight provides comprehensive insights about the Retinal Edema pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Retinal Edema companies, including Roche, Novartis, Bayer, Regeneron, AbbVie, Sanofi, Genentech, and Iveric Bio, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Retinal Edema Market Expected to Witness Significant Growth Through 2032, Driven by Recent FDA Approvals and a Robust Clinical Pipeline | DelveInsight

“Allergic Contact Dermatitis – Market Insight, Epidemiology And Market Forecast – 2032”

DelveInsight’s “Allergic Contact Dermatitis – Market Insight, Epidemiology And Market Forecast – 2032” report delivers an in-depth understanding of Allergic Contact Dermatitis, historical and forecasted epidemiology, as well as the market trends in the 7MM which include the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The report covers current treatment practices, emerging drugs, market share of individual therapies, competitive landscape, and allergic contact dermatitis market forecasts till 2032 across these major markets.

The allergic contact dermatitis market is expected to witness significant transformation during the forecast period (2024-2032) across 7MM, with the US representing the largest market share, followed by the EU countries and Japan. This growth is primarily attributed to the rising prevalence of contact allergies, increased environmental exposure to allergens, and advancements in treatment modalities that address the specific immunological pathways involved in this delayed hypersensitivity reaction.

Download the Allergic Contact Dermatitis market report to understand which factors are driving the ACD market trends @ Allergic Contact Dermatitis Market Trends.

According to allergic contact dermatitis epidemiological data, approximately 20% of the general population suffers from contact allergy to at least one allergen, with a significantly higher prevalence in women compared to men. Furthermore, the most common allergens implicated in allergic contact dermatitis include nickel, fragrances, cobalt, and preservatives, with medicament allergies increasingly recognized as responsible for approximately 27% of patch test-positive cases.

Discover evolving trends in the Allergic Contact Dermatitis patient pool forecasts @ Allergic Contact Dermatitis Epidemiological Analysis.

The current treatment landscape for allergic contact dermatitis primarily involves allergen identification and avoidance as the definitive approach, supplemented by topical corticosteroids to manage symptoms. Tacrolimus ointment has emerged as a promising alternative, particularly for sensitive areas like the eyelids, by inhibiting T-lymphocyte activation and dermal Langerhans’ cells without the side effects associated with corticosteroids. Studies have demonstrated significant improvement in erythema, edema, scaling, and lichenification after 30 days of treatment with topical tacrolimus.

The allergic contact dermatitis pipeline is expanding, with several pharmaceutical companies investing in the development of novel therapeutics targeting specific pathways in the allergic cascade, aiming to provide alternatives to traditional corticosteroid therapies. The leading candidate includes EB-01 (daniluromer) by Edesa Biotech, a topical phospholipase A2 inhibitor that has shown positive results in Phase IIb trials for moderate-to-severe ACD. Other companies active in this space include Allakos, Hapten Sciences, and ILiAD Biotechnologies, with investigational drugs targeting pathways such as the glucocorticoid and prostaglandin D2 receptors, though most of these are still in preclinical stages.

Recent clinical insights have enhanced understanding of the relationship between allergic contact dermatitis and other inflammatory skin conditions. Notably, there is growing recognition of the significant comorbidity between allergic contact dermatitis and atopic dermatitis, with recent systematic reviews suggesting that ACD is a clinically important problem in both children and adults with atopic dermatitis. This overlap presents both challenges in diagnosis and opportunities for developing therapeutic approaches that address multiple inflammatory pathways.

Recently, in December 2024, the FDA approved VTAMA cream for atopic dermatitis in adults and children as young as two, marking a milestone as a non-steroidal topical therapy with no label warnings or restrictions on duration or body surface area treated. Additionally, a March 2025 review highlights that emerging therapies such as biologics (e.g., dupilumab) and JAK inhibitors (e.g., abrocitinib, upadacitinib) are showing promising results, especially for patients with refractory allergic contact dermatitis.

Discover evolving trends in the Allergic Contact Dermatitis treatment landscape @ Allergic Contact Dermatitis Recent Developments.

Despite advancements, substantial challenges persist in the allergic contact dermatitis landscape. The complex and multifactorial nature of allergic contact dermatitis makes diagnosis challenging, with patch testing remaining the gold standard despite its limitations. Furthermore, the increasing prevalence of medicament allergies, particularly to topical antibiotics and antifungals, complicates treatment approaches. In a recent study, framycetin, miconazole, and econazole were identified as the three most common positive medicament reactions, highlighting the importance of comprehensive patch testing panels that include medicaments.

Looking ahead, the allergic contact dermatitis market is expected to witness significant transformation through 2032, driven by enhanced understanding of disease pathogenesis, development of novel therapeutic approaches, and advances in diagnostic methodologies. The integration of biomarker-guided precision medicine approaches and the exploration of new drug delivery systems are further anticipated to reshape the treatment landscape.

DelveInsight’s report emphasizes that successful navigation of the evolving allergic contact dermatitis therapeutic market will require a multifaceted approach focusing on improved allergen identification, development of targeted therapeutics, and enhanced education for both healthcare providers and patients regarding allergen avoidance strategies.

Table of Contents

1. Key Insights

2. Executive Summary of Allergic Contact Dermatitis

3. Allergic Contact Dermatitis Competitive Intelligence

4. Allergic Contact Dermatitis: Market Overview at a Glance

5. Allergic Contact Dermatitis: Disease Background and Overview

6. Patient Journey

7. Allergic Contact Dermatitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Allergic Contact Dermatitis Unmet Needs

10. Key Endpoints of Allergic Contact Dermatitis Treatment

11. Allergic Contact Dermatitis Marketed Products

12. Allergic Contact Dermatitis Emerging Therapies

13. Allergic Contact Dermatitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Allergic Contact Dermatitis

17. KOL Views

18. Allergic Contact Dermatitis Market Drivers

19. Allergic Contact Dermatitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Allergic Contact Dermatitis Market Poised for Expansion Through 2032, Driven by Recent FDA Approvals and Emerging Therapies Targeting Specific Immune Pathways | DelveInsight